Year: 2023

WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights. “Acrivon remains committed to being science and data-driven as we continue advancing our clinical and preclinical pipeline of precision oncology medicines, enabled by our highly differentiated Acrivon Predictive Precision Proteomics (AP3) platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president,...

Contracted revenue of $1.81 billion, interest rate risk fully hedged, sustainable quarterly dividend of $0.375 per common share LONDON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship Lease” or “GSL”), an owner of containerships, announced today its unaudited results for the three and nine months ended September 30, 2023. Third Quarter 2023 and Year to Date Highlights – Reported operating revenue of $174.5 million for the third quarter 2023, up 1.2% from $172.5 million for the prior year period. For the nine months ended September 30, 2023, operating revenue was $495.9 million, up 3.2% from $480.6 million in the prior year period. – Reported net income available to common shareholders of $82.7 million for the third quarter 2023, a decrease of 7.7% on net income of $89.6...

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023. “We continue to make important progress in advancing THB335, our orally available KIT inhibitor, towards clinical trials in the first half of 2024, which we believe has the potential to be a transformative treatment for chronic spontaneous urticaria and other mast cell-driven diseases,” said Natalie Holles, Chief Executive Officer of Third Harmonic...

Revenue of $21.1M and Adjusted EBITDA* of $866K for First Six Months Fiscal 2024 Senior Management Will Host a Live Conference Call and Audio Webcast Beginning at 1:30 P.M. ET on Thursday, November 9, 2023LOS ANGELES, CA, Nov. 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — PodcastOne (Nasdaq: PODC), a leading podcast platform and a subsidiary of LiveOne (Nasdaq: LVO), announced today its operating results for the second fiscal quarter of its fiscal year ending March 31, 2024 (“Q2 Fiscal 2024”). PodcastOne’s President and Co-Founder, Kit Gray, commented, “As we continue to execute across all aspects of our business, we expect to report both record revenue and record positive Adjusted EBITDA in Fiscal 2024. Moreover, we remain opportunistic with respect to acquiring accretive podcast shows and podcast networks.” Recent...

CASTLE ROCK, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) — Core verification and certification revenue increases but total revenue decreases slightly based on lower hardware sales due primarily to cyclical herd contraction Third Quarter Highlights – 2023 vs. 2022Verification and certification revenue up 4% to $5.4 million from $5.2 million Product sales decline 23% to $1.2 million from $1.6 million Total revenue down 4% to $7.0 million from $7.3 million Net income decreased 8% to $723,000 from $785,000 Diluted EPS flat at $0.13 Adjusted EBITDA of $1.2 million vs. $1.3 million Company buys back $855,000 of its stock in Q3, or 60,537 shares; diluted share count drops to 5,658,000 from 6,016,000 year over yearNine-Month Highlights – 2023 vs. 2022Verification and certification revenue up 8% to $13.9 million from $12.9 million Product...

Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescents Data from all adult patients in BEACON to be presented in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023), including the preliminary analysis of the precedented pivotal endpoint, cumulative time in sunlight over 6 months on days without pain Preliminary pharmacodynamic data from the ongoing phase 1b/2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia to be presented in a poster at ASH 2023, including changes in hemoglobin levels Data from the first 28 mg cohort of the phase 1b/2 study of DISC-0974 in patients with anemia of chronic kidney disease who are not receiving dialysis (NDD-CKD) to be presented as a part of a management...

Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and nine months ended September 30, 2023, and provided a corporate update. “In the third quarter 2023, we once again achieved all-time highs across several leading indicators, including net revenue, Twirla demand, factory sales,...